Board of Directors

Robin L. Smith, MD, MBA, President and Chairman of the Board

Robin L. Smith, M.D., MBA, is a business leader, entrepreneur, medical doctor and philanthropist. She received her Bachelor of Arts degree from Yale University and her M.D. degree from the Yale School of Medicine. Dr. Smith holds an MBA degree from the Wharton School of Business and completed the Stanford University Directors Program. In 2019, Dr. Smith received an honorary Doctor of Science degree from Thomas Jefferson Medical College. She is a trailblazer in the fields of regenerative medicine and predictive analytics and has focused on turnarounds, M&A and disruptive innovations driving interest and growth.


Dr. Smith is the founder, president and chairman of the board of the Cura Foundation and Stem for Life since 2007. She is also vice president and director of the Science and Faith (STOQ) Foundation at the Vatican. Dr. Smith is a member of the board of trustees of Sanford Health, the board of overseers of the New York University Langone Medical Center in New York, and a board member of the Alliance for Cell Therapy Now and OPA Health and is active in the NFL Alumni Association’s Regenerative Medicine and Cell Therapy initiative. Dr. Smith previously served on the Sanford Health’s International Board, the board of trustees of the New York University Langone Medical Center, was chairman of the board of directors of the New York University Hospital for Joint Diseases and served on the board of the Alliance for Regenerative Medicine (ARM) Foundation.


Dr. Smith also has extensive experience serving on the boards of directors and board committees of multiple public companies. She currently serves on the board of directors of Sorrento Therapeutics (NASDAQ: SRNE) through November 15, 2021, Celularity Inc (NASDAQ: CELU), a Celgene spin-out focused on cancer and regenerative medicine, the newly formed SPAC Western Acquisition Ventures, as well as private companies Spiritus Therapeutics and Vcinity Inc.


Dr. Smith co-authored “Cells Are the New Cure” (2017) and “The Healing Cell: How the Greatest Revolution in Medical History Is Changing Your Life” (2013). She was appointed as clinical associate professor, Department of Medicine, Rutgers New Jersey Medical School in 2017. She has also been widely recognized for her leadership in health care and as a female entrepreneur.

Max Gomez, PhD, Trustee

One of TV’s most respected medical journalists, Dr. Max Gomez has produced award-winning health and science segments for network stations in New York and Philadelphia. Dr. Max has reported for “Dateline,” “The Today Show” and “48 Hours.” He is currently the senior medical correspondent for WCBS, the flagship CBS network station in New York.


Over nearly four decades, he’s earned nine Emmy® Awards, three New York State Broadcasters Association awards and UPI’s Best Documentary award.


In addition to NYC’s “Excellence in Time of Crisis” for his September 11 coverage, Dr. Max has been singled out nationally for special award recognition by the Leukemia and Lymphoma Society and The National Marfan Foundation. He was also named the American Health Foundation’s Man of the Year.


Dr. Gomez has served on the national board of directors for the American Heart Association, the Princeton Alumni Weekly, and Partnership for After School Education. He has chaired the national communications committees for the American Heart Association and the American Association for the Advancement of Science.


Dr. Max is the co-author of Cells are the New Cure – The Cutting Edge Medical Breakthroughs that are Transforming Our Health, Our Stem Cells – The Mysteries of Life and Secrets of Healing and The Prostate Health Program: A Guide to Preventing and Controlling Prostate Cancer.


Dr. Max is an honors graduate of Princeton University, received his Ph.D. in neuroscience from the Wake Forest University School of Medicine and was a U.S. National Institutes of Health postdoctoral fellow at Rockefeller University.

Steven G. Martin, Trustee

Mr. Steven Martin is the Managing Member and a founder of Aspire Capital Fund, LLC a Chicago-based investment fund started in 2010 which has invested over $250 million in small emerging growth companies. Aspire Capital is focused on investing in life science companies and promoting early stage clinical development of cellular therapies and regenerative medicine. Mr. Martin has thirty years of legal and financing experience and has funded or committed to fund over $1.5 billion in investments. During his career, Mr. Martin has invested in hundreds of development-stage companies and many emerging cell therapy companies catalyzing their growth.

In 1999, Mr. Martin also founded Fusion Capital, a private investment fund which over ten years funded small emerging growth companies with a focus on life science companies. Prior to Fusion Capital, Mr. Martin was a partner at the Chicago law firm of Katten Muchin Rosenman LLP. As an attorney, Mr. Martin represented institutional investors and companies in highly complex financings as well as venture capital and private equity transactions.

Mr. Martin received his Juris Doctor degree with honors from Northwestern University School of Law. Mr. Martin graduated with high honors from the University of Michigan with a Bachelors of Business Administration, concentrating in finance.